Cargando…

Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US

BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkind, Mitchell S. V., Witte, Klaus K., Kasner, Scott E., Sawyer, Laura M., Grimsey Jones, Frank W., Rinciog, Claudia, Tsintzos, Stelios, Rosemas, Sarah C., Lanctin, David, Ziegler, Paul D., Reynolds, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875401/
https://www.ncbi.nlm.nih.gov/pubmed/36698055
http://dx.doi.org/10.1186/s12872-023-03073-6
_version_ 1784877953025310720
author Elkind, Mitchell S. V.
Witte, Klaus K.
Kasner, Scott E.
Sawyer, Laura M.
Grimsey Jones, Frank W.
Rinciog, Claudia
Tsintzos, Stelios
Rosemas, Sarah C.
Lanctin, David
Ziegler, Paul D.
Reynolds, Matthew R.
author_facet Elkind, Mitchell S. V.
Witte, Klaus K.
Kasner, Scott E.
Sawyer, Laura M.
Grimsey Jones, Frank W.
Rinciog, Claudia
Tsintzos, Stelios
Rosemas, Sarah C.
Lanctin, David
Ziegler, Paul D.
Reynolds, Matthew R.
author_sort Elkind, Mitchell S. V.
collection PubMed
description BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The objective of this study was to evaluate the cost-effectiveness of ICMs compared to standard of care (SoC) for detecting AF in patients at high risk of stroke (CHADS(2) ≥ 2), in the US. METHODS: Using patient data from the REVEAL AF trial (n = 393, average CHADS(2) score = 2.9), a Markov model estimated the lifetime costs and benefits of detecting AF with an ICM or with SoC (specifically intermittent use of electrocardiograms and 24-h Holter monitors). Ischemic and hemorrhagic strokes, intra- and extra-cranial hemorrhages, and minor bleeds were modelled. Diagnostic and device costs, costs of treating stroke and bleeding events and medical therapy—specifically costs of NOACs were included. Costs and health outcomes, measured as quality-adjusted life years (QALYs), were discounted at 3% per annum, in line with standard practice in the US setting. One-way deterministic and probabilistic sensitivity analyses (PSA) were undertaken. RESULTS: Lifetime per-patient cost for ICM was $31,116 versus $25,330 for SoC. ICMs generated a total of 7.75 QALYs versus 7.59 for SoC, with 34 fewer strokes projected per 1000 patients. The model estimates a number needed to treat of 29 per stroke avoided. The incremental cost-effectiveness ratio was $35,528 per QALY gained. ICMs were cost-effective in 75% of PSA simulations, using a $50,000 per QALY threshold, and a 100% probability of being cost-effective at a WTP threshold of $150,000 per QALY. CONCLUSIONS: The use of ICMs to identify AF in a high-risk population is likely to be cost-effective in the US healthcare setting. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03073-6.
format Online
Article
Text
id pubmed-9875401
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98754012023-01-26 Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US Elkind, Mitchell S. V. Witte, Klaus K. Kasner, Scott E. Sawyer, Laura M. Grimsey Jones, Frank W. Rinciog, Claudia Tsintzos, Stelios Rosemas, Sarah C. Lanctin, David Ziegler, Paul D. Reynolds, Matthew R. BMC Cardiovasc Disord Research BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The objective of this study was to evaluate the cost-effectiveness of ICMs compared to standard of care (SoC) for detecting AF in patients at high risk of stroke (CHADS(2) ≥ 2), in the US. METHODS: Using patient data from the REVEAL AF trial (n = 393, average CHADS(2) score = 2.9), a Markov model estimated the lifetime costs and benefits of detecting AF with an ICM or with SoC (specifically intermittent use of electrocardiograms and 24-h Holter monitors). Ischemic and hemorrhagic strokes, intra- and extra-cranial hemorrhages, and minor bleeds were modelled. Diagnostic and device costs, costs of treating stroke and bleeding events and medical therapy—specifically costs of NOACs were included. Costs and health outcomes, measured as quality-adjusted life years (QALYs), were discounted at 3% per annum, in line with standard practice in the US setting. One-way deterministic and probabilistic sensitivity analyses (PSA) were undertaken. RESULTS: Lifetime per-patient cost for ICM was $31,116 versus $25,330 for SoC. ICMs generated a total of 7.75 QALYs versus 7.59 for SoC, with 34 fewer strokes projected per 1000 patients. The model estimates a number needed to treat of 29 per stroke avoided. The incremental cost-effectiveness ratio was $35,528 per QALY gained. ICMs were cost-effective in 75% of PSA simulations, using a $50,000 per QALY threshold, and a 100% probability of being cost-effective at a WTP threshold of $150,000 per QALY. CONCLUSIONS: The use of ICMs to identify AF in a high-risk population is likely to be cost-effective in the US healthcare setting. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03073-6. BioMed Central 2023-01-25 /pmc/articles/PMC9875401/ /pubmed/36698055 http://dx.doi.org/10.1186/s12872-023-03073-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Elkind, Mitchell S. V.
Witte, Klaus K.
Kasner, Scott E.
Sawyer, Laura M.
Grimsey Jones, Frank W.
Rinciog, Claudia
Tsintzos, Stelios
Rosemas, Sarah C.
Lanctin, David
Ziegler, Paul D.
Reynolds, Matthew R.
Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title_full Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title_fullStr Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title_full_unstemmed Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title_short Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
title_sort cost-effectiveness of an insertable cardiac monitor in a high-risk population in the us
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875401/
https://www.ncbi.nlm.nih.gov/pubmed/36698055
http://dx.doi.org/10.1186/s12872-023-03073-6
work_keys_str_mv AT elkindmitchellsv costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT witteklausk costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT kasnerscotte costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT sawyerlauram costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT grimseyjonesfrankw costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT rinciogclaudia costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT tsintzosstelios costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT rosemassarahc costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT lanctindavid costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT zieglerpauld costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus
AT reynoldsmatthewr costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus